Physician profile
Elena Jones
NPI 1134118771
$14,013.69
in general payments reported to CMS, 2019-2025
35 companies · $2,678 in 2025
The $2,678 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,401 · 2020: $1,590 · 2021: $1,425 · 2022: $1,169 · 2023: $2,427 · 2024: $2,324 · 2025: $2,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,114 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,114.43 |
| Education | $314.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,181.68 | 2019-2025 | Cabtreo, Jublia |
| Dermavant Sciences, INC. | $1,307.05 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $1,215.88 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $1,148.91 | 2019-2025 | |
| Ucb, INC. | $1,129.27 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $852.65 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $800.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $793.26 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $529.53 | 2019-2025 | |
| Incyte Corporation | $524.82 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $497.31 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $369.84 | 2022-2024 | Sotyktu |
| Almirall LLC | $317.01 | 2019-2021 | |
| Abbvie INC. | $315.49 | 2020-2025 | |
| Botanix Sb INC | $301.25 | 2025 | Sofdra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $259.35 | 2019-2025 | Adbry |
| Sanofi-Aventis U.S. LLC | $203.43 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $191.06 | 2019-2025 | Dupixent |
| Encore Dermatology INC. | $175.80 | 2019-2020 | |
| Journey Medical Corporation | $138.87 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $134.45 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $128.45 | 2020-2021 | |
| Organon LLC | $86.69 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $56.85 | 2023-2024 | Zoryve |
| Epi Health, LLC | $53.75 | 2019 | |
| Sebela Pharmaceuticals INC. | $51.45 | 2019-2021 | |
| Dermira, INC. | $51.45 | 2020 | |
| Verrica Pharmaceuticals INC. | $39.40 | 2023 | Ycanth |
| Allergan, INC. | $30.86 | 2019 | |
| Sandoz INC. | $24.11 | 2020 | |
| Amgen INC. | $23.65 | 2020 | |
| Aclaris Therapeutics, INC. | $23.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.69 | 2023 | Cyltezo |
| Merz North America, INC. | $17.62 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $16.61 | 2024 | Clear+Brilliant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.